Evidence map›Paper›PMID 34768849›Full record

ArticleInternational journal of molecular sciences2021

Comparative Antiseizure Analysis of Diverse Natural Coumarin Derivatives in Zebrafish.

Ewelina Kozioł, Krzysztof Jóźwiak, Barbara Budzyńska, Peter A M de Witte, Daniëlle Copmans, Krystyna Skalicka-Woźniak

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Multi-target Phenylpropanoids Against Epilepsy.Current neuropharmacology · 2024
    Review
  6. Treating Epilepsy with Natural Products: Nonsense or Possibility?Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  7. Article
  8. Evaluation of the Antiseizure Activity of Endemic PlantInternational journal of molecular sciences · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ewelina KoziołDepartment of Natural Products Chemistry, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland.
Krzysztof JóźwiakDepartment of Biopharmacy, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland.ORCID 0000-0001-6018-5092
Barbara BudzyńskaIndependent Laboratory of Behavioral Studies, Medical University of Lublin, 20-059 Lublin, Poland.ORCID 0000-0001-5917-9285
Peter A M de WitteLaboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-9989-9567
Daniëlle CopmansLaboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-9804-8410
Krystyna Skalicka-WoźniakDepartment of Natural Products Chemistry, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland.ORCID 0000-0002-9313-5929
Medical University of Lublin · PLKU Leuven · BE

Funding

KU Leuven Internal funding C3 contract number C32/17/044Medical Univeristy of Lublin DS 28National Science Center 2016/21/N/NZ4/03658
6 · The paper itself

Abstract

Coumarins are a well-known group of plant secondary metabolites with various pharmacological activities, including antiseizure activity. In the search for new antiseizure drugs (ASDs) to treat epilepsy, it is yet unclear which types of coumarins are particularly interesting as a systematic analysis has not been reported. The current study performed behavioral antiseizure activity screening of 18 different coumarin derivatives in the larval zebrafish pentylenetetrazole (PTZ) model using locomotor measurements. Activity was confirmed for seven compounds, which lowered seizure-like behavior as follows: oxypeucedanin 38%, oxypeucedanin hydrate 74%, notopterol 54%, nodakenetin 29%, hyuganin C 35%, daphnoretin 65%, and pimpinellin 60%. These coumarins, together with nodakenin, underwent further antiepileptiform analysis by local field potential recordings from the zebrafish opticum tectum (midbrain). All of them, except for nodakenetin, showed pronounced antiepileptiform activity, decreasing PTZ-induced elevation in power spectral density (PSD) by 83-89% for oxypeucedanin, oxypeucedanin hydrate, and notopterol, 77% for nodakenin, 26% for nodakenetin, 65% for hyuganin C, 88% for daphnoretin, and 81% for pimpinellin. These data demonstrate the potential of diverse coumarin scaffolds for ASD discovery. Finally, the structural differences between active and inactive coumarins were investigated in silico for oxypeucedanin hydrate and byacangelicin for their interaction with GABA-transaminase, a hypothetical target.

Indexed as

4-Aminobutyrate TransaminaseAnimalsAnticonvulsantsConvulsantsCoumarinsEpilepsyMesencephalonPentylenetetrazolePlant ExtractsSeizuresZebrafish4-Aminobutyrate TransaminaseAnticonvulsantsConvulsantsCoumarinsPentylenetetrazolePlant Extractsbehaviorcoumarinselectrophysiologyepilepsypentylenetetrazolezebrafish

Identifiers

PMID34768849
PMCPMC8584229
OpenAlexW3210128075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.